Pomerantz Law Firm Warns Investors of Potential Class Action Against Lantheus Holdings Due to Recent Financial Disclosures

Investor Alert: Class Action Lawsuit Filed Against Lantheus Holdings, Inc.

On October 13, 2025, Pomerantz LLP announced a class action lawsuit targeting Lantheus Holdings, Inc. (NASDAQ: LNTH), a company engaged in the development of targeted therapeutics. This legal action has been prompted by concerns over potential securities fraud and other unlawful business activities conducted by Lantheus and its executives. Affected investors are encouraged to reach out to Pomerantz's Danielle Peyton for assistance.

The lawsuit represents a critical development for investors who believe they may have suffered losses due to the company's recent financial performance and disclosures. As outlined by Pomerantz, investors are required to act swiftly, as they have until November 10, 2025, to apply for appointment as Lead Plaintiff in the class-action lawsuit if they purchased Lantheus securities during the specified Class Period. Inquiries to join the suit can be directed to Pomerantz through phone or email, with attendees advised to provide their contact details and the number of shares purchased.

Background on Lantheus Holdings

Lantheus has been a significant player in the field of oncology, particularly with its radiopharmaceutical product Pylarify. However, in its first quarter report for 2025, the company revealed results that fell short of market expectations. Sales for Pylarify dropped year-on-year due to what Lantheus described as a "temporal competitive disruption," leading to a downward revision of its earlier financial projections. Following the unsatisfactory earnings announcement on May 7, 2025, Lantheus's stock price saw a notable decline, plummeting by $24.35, equating to a 23.23% drop.

The downward spiral continued when the company's disappointing second quarter results were revealed on August 6, 2026. Here, Lantheus announced further declines in EPS and revenue, once again missing the market expectations and further lowering growth forecasts for Pylarify. Sales figures showed an 8.3% decrease compared to the previous year, exacerbated by intensifying competition that affected pricing strategies. Following this announcement, the stock dropped by $20.76, or 28.58%, closing at $51.87 per share.

Implications for Investors

Investors holding Lantheus shares during this tumultuous period are now at a crossroads. The class action lawsuit not only signifies a collective push for accountability from the company's leadership but also offers a potential avenue for recovery for those who have faced financial harm. Pomerantz LLP, with its extensive history in handling corporate and securities litigation, stresses the importance of standing together in pursuing justice for any deceptive practices identified.

Founded in the early 20th century, Pomerantz has established itself as a powerhouse in the realm of class action litigation, with a strong track record of achieving favorable settlements for affected investors. Their commitment to fighting against breaches of fiduciary duty and securities fraud is unwavering, and this latest class action against Lantheus epitomizes their ongoing mission to protect shareholder rights.

Conclusion

With critical deadlines imminent, investors who might qualify are urged not to delay in contacting Pomerantz LLP for more information on how to potentially join this class action. The outcome of this legal pursuit may hold significant ramifications for Lantheus Holdings and its investors, particularly in light of the recent financial hardships the company has encountered. As this situation unfolds, stakeholders are reminded of the importance of vigilance in the complex landscape of corporate accountability and investor rights.